KERYX BIOPHARMACEUTICALS INC Form 8-K April 18, 2011

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

**CURRENT REPORT** 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 18, 2011

Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation) 000-30929 (Commission File Number) 13-4087132 (IRS Employer Identification No.)

750 Lexington Avenue New York, New York 10022 (Address of Principal Executive Offices)

(212) 531-5965

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- £ Written communications pursuant to Rule 425 under the Securities Act.
  - £ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- £ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- £ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

#### Item 8.01. Other Events

On April 18, 2011, Keryx Biopharmaceuticals, Inc. issued a press release announcing that its Japanese partner for Zerenex<sup>TM</sup> (ferric citrate), Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co., Ltd., JT's pharmaceutical business subsidiary, has commenced a Phase 3 clinical program of ferric citrate in Japan for the treatment of patients with hyperphosphatemia. A copy of such press release is being furnished as Exhibit 99.1 to this report.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 $Keryx\ Biopharmaceuticals,\ Inc.$ 

(Registrant)

Date: April 18, 2011 By: /s/ James F. Oliviero

James F. Oliviero Chief Financial Officer

## INDEX TO EXHIBITS

# Exhibit NumberDescription

99.1 Press Release dated April 18, 2011.